Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559252 | 0.88 | CYP19A1 (0.51) | ALDH1A1MAPTCYP19A1IMPDH2IMPDH1 | |
| SCHEMBL24337996 | 0.88 | CYP19A1 (0.51) | ALDH1A1MAPTCYP19A1IMPDH2IMPDH1 | |
| SCHEMBL29489124 | 0.82 | CA1 (0.54) | CA1CA2ALDH1A1MAPTIMPDH2 | |
| SCHEMBL45954 | 0.82 | CA1 (0.54) | CA1CA2ALDH1A1MAPTIMPDH2 | |
| SCHEMBL2940694 | 0.82 | SLC6A2 (0.42) | CA1CA2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3883853 | 0.82 | ALDH1A1 (0.40) | CA1CA2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL30496165 | 0.80 | ALDH1A1 (0.49) | CA1CA2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL483697 | 0.80 | ALDH1A1 (0.49) | CA1CA2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28215006 | 0.79 | S1PR1 (0.40) | CA1CA2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3034972 | 0.79 | APOBEC3G (0.48) | MAPTSMN1; SMN2HTTKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288057-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | NOVARTIS AG (CH) | 2011-11-24 | — | — | US | disclosed |
| CN-102186803-A | Salicylic acid derivatives being farnesyl pyrophosphate synthase activity inhibitors | NOVARTIS AG | 2011-09-14 | — | — | CN | disclosed |
| EP-2342173-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | Novartis AG (CH) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010043584-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | NOVARTIS AG (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288057-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | FDPS, GGPS1, COASY | CA1 4343/4885CA2 3427/4885ALDH1A1 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.